Gene therapy for cardiomyocytes, a heart beat away

Gene Therapy

Volumn 16, Issue 6, 2009, Pages 707-708

  McPhee, S W J ^a   Samulski, R J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATASE (CALCIUM); BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR KINASE; CALCIUM; G PROTEIN COUPLED RECEPTOR KINASE 2; METOPROLOL; PHOSPHOLAMBAN; PHOSPHOPROTEIN PHOSPHATASE 1; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; VIRUS VECTOR;

ADJUVANT THERAPY; ANTIOXIDANT ACTIVITY; CALCIUM CELL LEVEL; CARDIOMYOPATHY; CARDIOVASCULAR GENE THERAPY; CLINICAL TRIAL; DRUG MECHANISM; GENE EXPRESSION; GENE TRANSFER; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTILITY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HEART RATE; HEART VENTRICLE FUNCTION; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SYSTOLIC DYSFUNCTION; VIRAL GENE DELIVERY SYSTEM;

BETA-ADRENERGIC RECEPTOR KINASES; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEART FAILURE; HUMANS; MYOCYTES, CARDIAC;

EID: 67349265629     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.40     Document Type: Note

References (7)

1. Rengo G, Lymperopoulos A, Zincarelli C, Donniacuo M, Soltys S, Rabinowitz JE et al. Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure. Circulation 2009; 119: 89-98.
2. Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States: A poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999; 159: 505-510.
3. Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S et al Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: Critical role for expression level. Circulation 2000; 101: 1707-1714.
4. Shah AS, White DC, Emani S, Kypson AP, Lilly RE, Wilson K et al. In vivo ventricular gene delivery of a beta-adrenergic receptor kinase inhibitor to the failing heart reverses cardiac dysfunction. Circulation 2001; 103: 1311-1316.
5. Ly H, Kawase Y, Yoneyama R, Hajjar RJ. Gene therapy in the treatment of heart failure. Physiology 2007; 22: 81-96.
6. Hajjar RJ, Zsebo K, Deckelbaum L, Thompson C, Rudy J, Yaroshinsky A et al. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J Card Fail 2008; 14: 355-367.
7. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-inhuman phase 1/2 clinical trial. J Card Fail 2009; 15: 171-181.